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Discussion
Dr Ralph A. Schmid (Berne, Switzerland). Did you look at
liver function in the animal studies? When you give FasL system-
ically, animals die of liver failure.
Dr Stewart. Actually, those studies came from intraperitoneal
injection of Jo2 agonistic antibodies to Fas, and there was massive
hepatic necrosis in those previous studies. However, with our
intraperitoneal injections of Fas, we saw no changes in liver mor-
phology, as evidenced by hematoxylin and eosin staining.
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